The kidney, a cardiovascular risk marker, and a new target for therapy

Slides:

Advertisements

Similar presentations

Volume 54, Pages S135-S139 (December 1998)

Advertisements

Pathophysiology of renal fluid retention

LDL cholesterol in CKD—to treat or not to treat?

Plasma sodium and hypertension

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Mitchell H. Rosner, W. Kline Bolton Kidney International

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan

Progression of renal failure and hypertensive nephrosclerosis

Pathophysiology of renal fluid retention

Francesco Paolo Schena Kidney International

Need for better diabetes treatment for improved renal outcome

Overcoming barriers that inhibit proper treatment of anemia

Volume 70, Pages S21-S25 (December 2006)

Volume 57, Pages S32-S37 (April 2000)

Volume 79, Issue 12, Pages (June 2011)

Homocysteine and risk in end-stage renal disease: a matter of context

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

Progression of diabetic nephropathy

Anemia as a risk factor for chronic kidney disease

A new era in phosphate binder therapy: What are the options?

Volume 82, Issue 3, Pages (August 2012)

Volume 70, Issue 11, Pages (December 2006)

Benefits of preserving residual renal function in peritoneal dialysis

Study of Heart and Renal Protection (SHARP)

LDL cholesterol in CKD—to treat or not to treat?

Volume 74, Issue 8, Pages (October 2008)

Acute myocardial infarction in patients with end-stage renal disease

Volume 71, Issue 6, Pages (March 2007)

Volume 65, Issue 6, Pages (June 2004)

Blood pressure targets in hemodialysis patients

Amit X. Garg, William F. Clark, R. Brian Haynes, Andrew A. House

Fructose intake as a risk factor for kidney stone disease

Volume 78, Issue 8, Pages (October 2010)

Volume 74, Issue 4, Pages (August 2008)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia

Volume 87, Issue 1, Pages (January 2015)

Volume 67, Pages S52-S54 (January 2005)

Volume 63, Issue 2, Pages (February 2003)

Lynda Anne Szczech, Ira L. Lazar Kidney International

Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival.

Cardiovascular calcification in patients with chronic renal failure: Are we on target with this risk factor? Peter A. Mccullough, Sandeep Soman Kidney.

Volume 54, Pages S135-S139 (December 1998)

A man with a hole in his penis

Homocysteine, renal function, and risk of cardiovascular disease

Folkert W. Asselbergs, Hans L. Hillege, Wiek H. Van Gilst

Volume 67, Pages S55-S62 (January 2005)

Volume 66, Pages S18-S21 (November 2004)

Volume 64, Issue 2, Pages (August 2003)

Opportunities for a chronic disease outreach program in China

Volume 55, Pages S3-S16 (June 1999)

The Danish Renal Biopsy Register

Volume 60, Issue 3, Pages (September 2001)

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Michael R. Lattanzio, Matthew R. Weir Kidney International

Is it the low-protein diet or simply the salt restriction?

Cardiovascular risk in chronic kidney disease

Volume 64, Issue 4, Pages (October 2003)

Is complement a target for therapy in renal disease?

Volume 67, Issue 5, Pages (May 2005)

Volume 66, Pages S7-S10 (November 2004)

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

James B. Young, Hans-Hellmut Neumayer, Robert D. Gordon

Evaluation of the Losartan in Hemodialysis (ELHE) Study

Wendy E. Hoy, Megan Rees, Emma Kile, John D. Mathews, Zhiqiang Wang

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger Kidney.

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

The kidney, a cardiovascular risk marker, and a new target for therapy Dick De Zeeuw, Hans L. Hillege, Paul E. De Jong Kidney International Volume 68, Pages S25-S29 (September 2005) DOI: 10.1111/j.1523-1755.2005.09805.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 The effect of ACE-inhibition treatment to protect the heart after myocardial infarction is effective, particularly in those with reduced renal function. Data from [3]. Kidney International 2005 68, S25-S29DOI: (10.1111/j.1523-1755.2005.09805.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Blood pressure and albuminuria as predictors of morbidity and mortality. Left panel shows the total mortality data from the Life Insurance data (1.3 million subjects 1925-1939) with increasing systolic blood pressure. Right panel shows the data from the PREVEND study showing CV mortality in relation to baseline albuminuria levels [11]. Kidney International 2005 68, S25-S29DOI: (10.1111/j.1523-1755.2005.09805.x) Copyright © 2005 International Society of Nephrology Terms and Conditions